Product Information
Registration Status: ActiveSIN15023P
MABTHERA SOLUTION FOR SUBCUTANEOUS INJECTION 1400MG is approved to be sold in Singapore with effective from 2016-06-01. It is marketed by ROCHE SINGAPORE PTE LTD, with the registration number of SIN15023P.
This product contains Rituximab 1400mg in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by F. Hoffmann-La Roche Ltd in SWITZERLAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
Indication
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Mechanism of Action
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
Clearance
* 0.34 L/day [RA patients]
Active Ingredient/Synonyms
AntiCD20 | Rituximab |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.